search
Back to results

Iron Repletion in Chronic Cough and Iron Deficiency (CID)

Primary Purpose

Cough, Laryngeal Disease, Bronchial Disease

Status
Completed
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
iron sulphate
antiH1-histamine, proton pump inhibitor
Sponsored by
University of Turin, Italy
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Cough focused on measuring Cough, Laryngismus, Bronchial spasm, Deficiency diseases

Eligibility Criteria

15 Years - 70 Years (Child, Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Unexplained cough : no detectable trigger for chronic cough identified, such as persistent rhinitis, chronic sinusitis, gastroesophageal reflux disease and asthma.
  • no benefit by prior treatment with antiH1-histaminic drug and proton pump inhibitor.
  • iron deficiency.
  • normal lung function tests and chest radiography no relevant systemic disease.
  • no acute respiratory infection in the last eight weeks.
  • no pharmacological treatment in the last two weeks.

Exclusion Criteria:

Sites / Locations

  • Respiratory Pathophysiology Clinic, ASO San Giovanni Battista

Outcomes

Primary Outcome Measures

Change in cough VAS
Changes in cough VAS after 2 months iron supplementation (1 mg/kg elemental iron, corresponding to one or two 330 mg iron sulphate tablets)compared to the value observed after empiric treatment Cough VAS from 0 (best= no cough) to 5 (worst = severe cough)
Change in laryngeal histamine threshold
Change in laryngeal threshold, assessed as the histamine concentration causing 25% decrease from baseline of MIF50 (PC25MIF50), after 2 months iron supplementation (1 mg/kg elemental iron, corresponding to one or two 330 mg iron sulphate tablets), compared to the value obtained after empiric treatment
Change in cough histamine threshold
Change in cough threshold, assessed as the histamine concentration causing 5 or more coughs(PC5cough), after 2 months iron supplementation (1 mg/kg elemental iron, corresponding to one or two 330 mg iron sulphate tablets), compared to the value obtained after empiric treatment

Secondary Outcome Measures

Change in bronchial histamine threshold
Change in bronchial threshold, assessed as the histamine concentration causing 20% decrease from baseline of FEV1 (PC20FEV1), after 2 months iron supplementation (1 mg/kg elemental iron, corresponding to one or two 330 mg iron sulphate tablets), compared to the value obtained after empiric treatment

Full Information

First Posted
December 29, 2011
Last Updated
January 8, 2012
Sponsor
University of Turin, Italy
Collaborators
Regione Piemonte
search

1. Study Identification

Unique Protocol Identification Number
NCT01507792
Brief Title
Iron Repletion in Chronic Cough and Iron Deficiency
Acronym
CID
Official Title
Effect of Iron Repletion in Women With Chronic Cough and Iron Deficiency
Study Type
Interventional

2. Study Status

Record Verification Date
January 2012
Overall Recruitment Status
Completed
Study Start Date
January 2002 (undefined)
Primary Completion Date
January 2011 (Actual)
Study Completion Date
January 2011 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Turin, Italy
Collaborators
Regione Piemonte

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Chronic cough is more frequent and severe in women than in men. Women often have decreased iron stores, due to menses and pregnancies. Aim of the study: to investigate if iron deficiency has a role in chronic cough by favouring airway hypersensitivity to inhaled irritants.
Detailed Description
Women with chronic cough and iron deficiency, cough unresponsive to empiric treatment (suggested by cough guidelines) with antiH1-histaminic drug plus proton pump inhibitor. Cough VAS (score from 1,best, to 5, worst). Histamine inhalation challenge, performed to assess bronchial, laryngeal, and cough thresholds, performed by delivering doubling concentrations, from 0.5 mg/ml up to 32 mg/ml, by a nebulizer. After each dose FEV1, as bronchial index, maximum mid-inspiratory flow (MIF50) as laryngeal index, and coughs number are assessed. Bronchial threshold is the concentration causing 20% decrease in FEV1, laryngeal threshold that causing 25% decrease in MIF50, cough threshold that causing 5 coughs. Histamine hyperresponsiveness of the bronchi (BHR), larynx (LHR) and cough (coughHR) are defined for thresholds equal or below 8 mg/ml. Histamine thresholds and cough VAS obtained in baseline, after cough empiric treatment with antiH1-histaminic and proton pump inhibitor, and after iron supplementation.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cough, Laryngeal Disease, Bronchial Disease, Iron Deficiency
Keywords
Cough, Laryngismus, Bronchial spasm, Deficiency diseases

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
22 (Actual)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
iron sulphate
Intervention Description
1 or 2 330 mg/daily iron sulphate oral tablets
Intervention Type
Drug
Intervention Name(s)
antiH1-histamine, proton pump inhibitor
Other Intervention Name(s)
AntiH1-histaminic drug = Loratadine 10 mg, Proton pump inhibitor = omeprazole 20 mg twice daily
Intervention Description
This is not an intervention of interest, but it is a selection criterion to define unexplained cough, as suggested by cough guidelines.
Primary Outcome Measure Information:
Title
Change in cough VAS
Description
Changes in cough VAS after 2 months iron supplementation (1 mg/kg elemental iron, corresponding to one or two 330 mg iron sulphate tablets)compared to the value observed after empiric treatment Cough VAS from 0 (best= no cough) to 5 (worst = severe cough)
Time Frame
after 2 months empiric treatment and 2 months iron supplementation
Title
Change in laryngeal histamine threshold
Description
Change in laryngeal threshold, assessed as the histamine concentration causing 25% decrease from baseline of MIF50 (PC25MIF50), after 2 months iron supplementation (1 mg/kg elemental iron, corresponding to one or two 330 mg iron sulphate tablets), compared to the value obtained after empiric treatment
Time Frame
after 2 months empiric treatment and 2 months iron supplementation
Title
Change in cough histamine threshold
Description
Change in cough threshold, assessed as the histamine concentration causing 5 or more coughs(PC5cough), after 2 months iron supplementation (1 mg/kg elemental iron, corresponding to one or two 330 mg iron sulphate tablets), compared to the value obtained after empiric treatment
Time Frame
after 2 months empiric treatment and 2 months iron supplementation
Secondary Outcome Measure Information:
Title
Change in bronchial histamine threshold
Description
Change in bronchial threshold, assessed as the histamine concentration causing 20% decrease from baseline of FEV1 (PC20FEV1), after 2 months iron supplementation (1 mg/kg elemental iron, corresponding to one or two 330 mg iron sulphate tablets), compared to the value obtained after empiric treatment
Time Frame
after 2 months empiric treatment and 2 months iron supplementation

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
15 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Unexplained cough : no detectable trigger for chronic cough identified, such as persistent rhinitis, chronic sinusitis, gastroesophageal reflux disease and asthma. no benefit by prior treatment with antiH1-histaminic drug and proton pump inhibitor. iron deficiency. normal lung function tests and chest radiography no relevant systemic disease. no acute respiratory infection in the last eight weeks. no pharmacological treatment in the last two weeks. Exclusion Criteria:
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Caterina B Bucca, MD
Organizational Affiliation
University of Turin, Italy
Official's Role
Principal Investigator
Facility Information:
Facility Name
Respiratory Pathophysiology Clinic, ASO San Giovanni Battista
City
Turin
ZIP/Postal Code
10126
Country
Italy

12. IPD Sharing Statement

Citations:
PubMed Identifier
21167571
Citation
Bucca CB, Bugiani M, Culla B, Guida G, Heffler E, Mietta S, Moretto A, Rolla G, Brussino L. Chronic cough and irritable larynx. J Allergy Clin Immunol. 2011 Feb;127(2):412-9. doi: 10.1016/j.jaci.2010.10.038. Epub 2010 Dec 16.
Results Reference
background
PubMed Identifier
21248188
Citation
Bucca CB, Culla B, Guida G, Sciascia S, Bellone G, Moretto A, Heffler E, Bugiani M, Rolla G, Brussino L. Unexplained chronic cough and vitamin B-12 deficiency. Am J Clin Nutr. 2011 Mar;93(3):542-8. doi: 10.3945/ajcn.110.000802. Epub 2011 Jan 19.
Results Reference
background
PubMed Identifier
23067033
Citation
Bucca C, Culla B, Brussino L, Ricciardolo FL, Cicolin A, Heffler E, Bugiani M, Rolla G. Effect of iron supplementation in women with chronic cough and iron deficiency. Int J Clin Pract. 2012 Nov;66(11):1095-100. doi: 10.1111/ijcp.12001.
Results Reference
derived

Learn more about this trial

Iron Repletion in Chronic Cough and Iron Deficiency

We'll reach out to this number within 24 hrs